Sun Pharmaceuticals Industries Ltd's Q3FY25 Quarter Results
- 01 Feb 2025
Result Summary
- Sun Pharmaceuticals Industries Ltd reported a 3.6% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 12.0%.
- Its expenses for the quarter were up by 3.0% QoQ and 8.2% YoY.
- The net profit decreased 4.1% QoQ and increased 13.8% YoY.
- The earnings per share (EPS) of Sun Pharmaceuticals Industries Ltd stood at 12.1 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 14141.08 | 13645.39 | 12630.90 | 3.6% | 12.0% |
Total Expenses | 10348.51 | 10047.51 | 9560.74 | 3.0% | 8.2% |
Profit Before Tax | 3476.40 | 3597.88 | 3000.35 | -3.4% | 15.9% |
Tax | 558.86 | 567.21 | 432.32 | -1.5% | 29.3% |
Profit After Tax | 2912.98 | 3037.33 | 2560.54 | -4.1% | 13.8% |
Earnings Per Share | 12.10 | 12.70 | 10.50 | -4.7% | 15.2% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Sun Pharmaceuticals Industries Ltd is a leading pharmaceutical company, primarily engaged in manufacturing and marketing pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company operates in the healthcare industry, focusing on specialty and generic medications. Sun Pharmaceuticals has a substantial presence in both the domestic and international markets. Over the years, Sun Pharmaceuticals has expanded its product portfolio through strategic acquisitions and research and development initiatives. Recent developments include continued efforts to expand their specialty product offerings and enhance their global market footprint. However, specific recent major developments are not available in the provided data.
Revenue
In the third quarter of FY25, Sun Pharmaceuticals Industries Ltd reported a total income of ₹14,141.08 crores, marking a quarter-over-quarter increase of 3.6% from ₹13,645.39 crores in Q2FY25. On a year-over-year basis, the total income showed a notable growth of 12.0% compared to ₹12,630.90 crores in Q3FY24. This data indicates a robust performance in revenue generation over the past year, reflecting the company's ability to expand its market share and potentially enhance its product offerings. The consistent rise in revenue highlights the company's operational effectiveness in leveraging its resources and capabilities to drive sales.
Profitability
For Q3FY25, Sun Pharmaceuticals Industries Ltd recorded a profit before tax of ₹3,476.40 crores, which is a decrease of 3.4% from the previous quarter's ₹3,597.88 crores. However, compared to the same quarter in the previous year (Q3FY24), there was an increase of 15.9% from ₹3,000.35 crores. The profit after tax for Q3FY25 stood at ₹2,912.98 crores, declining by 4.1% from the Q2FY25 profit of ₹3,037.33 crores, yet showcasing a 13.8% year-over-year growth from ₹2,560.54 crores in Q3FY24. Earnings per share in Q3FY25 was ₹12.10, down by 4.7% from ₹12.70 in Q2FY25, but up by 15.2% from ₹10.50 in Q3FY24. This data reflects a strong year-over-year improvement in profitability metrics despite the quarter-over-quarter decline.
Operating Metrics
Total expenses for Sun Pharmaceuticals Industries Ltd in Q3FY25 were ₹10,348.51 crores, increasing by 3.0% from ₹10,047.51 crores in Q2FY25 and 8.2% from ₹9,560.74 crores in Q3FY24. The tax expense for Q3FY25 was ₹558.86 crores, slightly lower by 1.5% compared to ₹567.21 crores in Q2FY25, but higher by 29.3% from ₹432.32 crores in Q3FY24. These figures suggest a controlled increase in operating expenses in line with revenue growth, while the tax expenses indicate variations due to changes in profit and potential tax rate adjustments. The data highlights the company's operational efficiency and tax management over the periods compared.
